Thyroid Cancer Education
Thyroid cancer management is evolving with RET-targeted therapies, BRAF/MEK combinations, and radioligand approaches changing treatment for advanced differentiated and anaplastic disease. Knowledge Med sessions help physicians navigate these advances through interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing thyroid cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Identifying RET-altered and BRAF V600E-mutated thyroid cancers for targeted therapy
- Managing radioactive iodine-refractory differentiated thyroid cancer
- Treating anaplastic thyroid cancer with BRAF/MEK inhibitor combinations
- Sequencing multi-kinase inhibitors (lenvatinib, sorafenib, cabozantinib) in advanced disease
What Sessions Cover
Knowledge Med Thyroid Cancer sessions use interactive case simulations to address these topics and more.
- RET-targeted therapy in advanced thyroid cancer: selpercatinib and pralsetinib
- BRAF V600E-directed treatment in anaplastic and papillary thyroid cancer
- Radioactive iodine-refractory disease: when and how to start systemic therapy
- Multi-kinase inhibitor selection and toxicity management
Interactive Thyroid Cancer Sessions
Case Simulations
Work through realistic thyroid cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key Thyroid Cancer clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a Thyroid Cancer Session
Third-party, non-promotional thyroid cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session